{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:31:20Z","timestamp":1759624280635,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1468,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Research Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.exphem.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T02:11:47Z","timestamp":1520475107000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model"],"prefix":"10.1016","volume":"62","author":[{"given":"Maile K.","family":"Hollinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Rivell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Kajigaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyvan","family":"Keyvanfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.03.001_bib0010","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2018.03.001_bib0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.exphem.2018.03.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.exphem.2018.03.001_bib0040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","article-title":"Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"28","author":"Turgeman","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.exphem.2018.03.001_bib0045","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdx159","article-title":"Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma","volume":"28","author":"Bulbul","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0050","doi-asserted-by":"crossref","first-page":"e4283","DOI":"10.1097\/MD.0000000000004283","article-title":"Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report","volume":"95","author":"Inadomi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.exphem.2018.03.001_bib0055","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy","volume":"80","author":"Michot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2018.03.001_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.12855","article-title":"The epidemiology of acquired aplastic anemia","volume":"93","author":"Young","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.03.001_bib0070","first-page":"76","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"2013","author":"Young","year":"2013","journal-title":"ASH Educ Book"},{"key":"10.1016\/j.exphem.2018.03.001_bib0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2002-01-0035","article-title":"Intracellular interferon-\u03b3 in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia","volume":"100","author":"Sloand","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.03.001_bib0080","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058","article-title":"Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia","volume":"85","author":"Rosenfeld","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.03.001_bib0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12935-014-0144-2","article-title":"Altered expression of T cell Immunoglobulin-Mucin (Tim) molecules in peripheral blood mononuclear cells in aplastic anemia","volume":"14","author":"Liu","year":"2014","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.exphem.2018.03.001_bib0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2008.01095.x","article-title":"Increased T cell immunoglobulin mucin-3 and its ligand in acquired aplastic anemia","volume":"81","author":"Zhang","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3109\/10428194.2013.772605","article-title":"Association between polymorphisms in PDCD1 gene and aplastic anemia in Chinese Han population","volume":"54","author":"Wu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2018.03.001_bib0100","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1007\/s00296-011-2127-0","article-title":"Polymorphisms in PDCD1 gene are not associated with aplastic anemia in Chinese Han population","volume":"32","author":"Ming","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.exphem.2018.03.001_bib0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2017.01.016","article-title":"High programmed death 1 expression on T cells in aplastic anemia","volume":"183","author":"Zhao","year":"2017","journal-title":"Immunol Lett"},{"key":"10.1016\/j.exphem.2018.03.001_bib0110","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.4049\/jimmunol.178.7.4159","article-title":"Minor antigen H60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells","volume":"178","author":"Chen","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0115","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.4049\/jimmunol.179.8.5064","article-title":"PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues","volume":"179","author":"Keir","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0120","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0125","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","article-title":"Programmed death-1 controls T cell survival by regulating oxidative metabolism","volume":"194","author":"Tkachev","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2018.03.001_bib0135","doi-asserted-by":"crossref","first-page":"e1001347","DOI":"10.1371\/journal.ppat.1001347","article-title":"Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection","volume":"7","author":"Chen","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.exphem.2018.03.001_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaut.2011.02.009","article-title":"Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis","volume":"36","author":"Thangavelu","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.exphem.2018.03.001_bib0145","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2015-06-652453","article-title":"IFN-\u03b3-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.03.001_bib0150","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.13412","article-title":"Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia","volume":"94","author":"Hu","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.03.001_bib0155","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4049\/jimmunol.180.3.1309","article-title":"Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation","volume":"180","author":"Joshi","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0160","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0301-472X(01)00736-6","article-title":"Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia","volume":"29","author":"Kook","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2018.03.001_bib0170","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","article-title":"PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy","volume":"129","author":"Asano","year":"2017","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1830119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1830119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:46Z","timestamp":1759566766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1830119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":33,"alternative-id":["S0301472X1830119X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.03.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH \u2013 Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}